Natural Killer t cell-mediated immunotherapy for malignant diseases

Frontiers in Bioscience - Scholar

Volumn 1 S, Issue 1, 2009, Pages 108-116

  Motohashi, Shinichiro ^a   Nakayama, Toshinori ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Clinical trial; Dendritic cell; Immunotherapy; NKT cell; Review

Indexed keywords

ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 77954466011     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/e10     Document Type: Review

References (41)

1. M. Taniguchi, M. Harada, S. Kojo, T. Nakayama and H. Wakao: The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21, 483-513 (2003) (Pubitemid 37174539)
2. A. Bendelac, P. B. Savage and L. Teyton: The biology of NKT cells. Annu Rev Immunol 25, 297-336 (2007) (Pubitemid 46697911)
3. T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki and M. Taniguchi: CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 278, 1626-9 (1997) (Pubitemid 27516282)
4. F. M. Spada, Y. Koezuka and S. A. Porcelli: CD1drestricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188, 1529-34 (1998) (Pubitemid 28489590)
5. L. Brossay, M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona and M. Kronenberg: CD1dmediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188, 1521-8 (1998) (Pubitemid 28489589)
6. T. Kawano, T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, T. Fujisawa, H. Shinkai and M. Taniguchi: Antitumor cytotoxicity mediated by ligand-activated human Valpha24 NKT cells. Cancer Res 59, 5102-5 (1999) (Pubitemid 29503967)
7. J. E. Gumperz, S. Miyake, T. Yamamura and M. B. Brenner: Functionally distinct subsets of CD1drestricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195, 625-36 (2002) (Pubitemid 34461507)
8. M. Nieda, A. Nicol, Y. Koezuka, A. Kikuchi, N. Lapteva, Y. Tanaka, K. Tokunaga, K. Suzuki, N. Kayagaki, H. Yagita, H. Hirai and T. Juji: TRAIL expression by activated human CD4+Valpha24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97, 2067-74 (2001) (Pubitemid 32239088)
9. S. Fujii, K. Shimizu, C. Smith, L. Bonifaz and R. M. Steinman: Activation of natural killer T cells by alphagalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198, 267-79 (2003) (Pubitemid 36987852)
10. C. Carnaud, D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka and A. Bendelac: Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163, 4647-50 (1999) (Pubitemid 29501223)
11. M. J. Smyth, N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita and D. I. Godfrey: Sequential production of interferon-gamma by NK1.1 (+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99, 1259-66 (2002) (Pubitemid 34547079)
12. S. Fujii, K. Liu, C. Smith, A. J. Bonito and R. M. Steinman: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199, 1607-18 (2004) (Pubitemid 38821994)
13. E. Kobayashi, K. Motoki, T. Uchida, H. Fukushima and Y. Koezuka: KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7, 529-34 (1995) (Pubitemid 26077987)
14. T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, Y. Tanaka and M. Taniguchi: Natural killer-like nonspecific tumor cell lysis mediated by specific ligandactivated Valpha14 NKT cells. Proc Natl Acad Sci U S A 95, 5690-3 (1998) (Pubitemid 28224157)
15. I. Toura, T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai and M. Taniguchi: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163, 2387-91 (1999) (Pubitemid 29399156)
16. S. Fujii, K. Shimizu, M. Kronenberg and R. M. Steinman: Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3, 867-74 (2002)
17. Y. Akutsu, T. Nakayama, M. Harada, T. Kawano, S. Motohashi, E. Shimizu, T. Ito, N. Kamada, T. Saito, H. Matsubara, Y. Miyazawa, T. Ochiai and M. Taniguchi: Expansion of lung Valpha14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 93, 397-403 (2002) (Pubitemid 34506249)
18. P. R. Rogers, A. Matsumoto, O. Naidenko, M. Kronenberg, T. Mikayama and S. Kato: Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods 285, 197-214 (2004) (Pubitemid 38224562)
19. S. Fujii, K. Shimizu, R. M. Steinman and M. V. Dhodapkar: Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramidepulsed dendritic cells. J Immunol Methods 272, 147-59 (2003) (Pubitemid 36050752)
20. S. Motohashi, A. Ishikawa, E. Ishikawa, M. Otsuji, T. Iizasa, H. Hanaoka, N. Shimizu, S. Horiguchi, Y. Okamoto, S. Fujii, M. Taniguchi, T. Fujisawa and T. Nakayama: A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12, 6079-86 (2006) (Pubitemid 44703772)
21. K. Shimizu, M. Hidaka, N. Kadowaki, N. Makita, N. Konishi, K. Fujimoto, T. Uchiyama, F. Kawano, M. Taniguchi and S. Fujii: Evaluation of the function of human invariant NKT cells from cancer patients using alphagalactosylceramide- loaded murine dendritic cells. J Immunol 177, 3484-92 (2006) (Pubitemid 44277870)
22. S. Motohashi, S. Kobayashi, T. Ito, K. K. Magara, O. Mikuni, N. Kamada, T. Iizasa, T. Nakayama, T. Fujisawa and M. Taniguchi: Preserved IFN-gamma production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 102 159-65 (2002) (Pubitemid 35168029)
23. J. W. Molling, W. Kolgen, H. J. van der Vliet, M. F. Boomsma, H. Kruizenga, C. H. Smorenburg, B. G. Molenkamp, J. A. Langendijk, C. R. Leemans, B. M. von Blomberg, R. J. Scheper and A. J. van den Eertwegh: Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116, 87-93 (2005) (Pubitemid 40827759)
24. K. M. Dhodapkar, B. Cirignano, F. Chamian, D. Zagzag, D. C. Miller, J. L. Finlay and R. M. Steinman: Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109, 893-9 (2004) (Pubitemid 38500746)
25. S. M. Tahir, O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk and M. A. Exley: Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167, 4046-50 (2001) (Pubitemid 32910851)
26. K. Yanagisawa, K. Seino, Y. Ishikawa, M. Nozue, T. Todoroki and K. Fukao: Impaired proliferative response of Valpha24 NKT cells from cancer patients against alphagalactosylceramide. J Immunol 168, 6494-9 (2002) (Pubitemid 34620075)
27. J. Konishi, K. Yamazaki, H. Yokouchi, N. Shinagawa, K. Iwabuchi and M. Nishimura: The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 65, 1377-88 (2004) (Pubitemid 39539204)
28. S. Fujii, K. Shimizu, V. Klimek, M. D. Geller, S. D. Nimer and M. V. Dhodapkar: Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 122, 617-22 (2003) (Pubitemid 36995216)
29. M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar and J. Krasovsky: A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197, 1667-76 (2003) (Pubitemid 36745342)
30. J. W. Molling, J. A. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bontkes, H. J. van der Vliet, B. M. von Blomberg, R. J. Scheper and A. J. van den Eertwegh: Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25, 862-8 (2007) (Pubitemid 350002887)
31. T. Tachibana, H. Onodera, T. Tsuruyama, A. Mori, S. Nagayama, H. Hiai and M. Imamura: Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11, 7322-7 (2005) (Pubitemid 41507690)
32. G. Giaccone, C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, M. Roelvink, J. Beijnen, H. Zwierzina and H. M. Pinedo: A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8, 3702-9 (2002) (Pubitemid 35424759)
33. A. Ishikawa, S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi and T. Fujisawa: A phase I study of alphagalactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11, 1910-7 (2005) (Pubitemid 40471857)
34. + natural killer T-cell activation by alpha- galactosylceramide. Int J Cancer 117, 265-73 (2005) (Pubitemid 41377447)
35. M. Nieda, M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D. J. Macfarlane and A. J. Nicol: Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383-9 (2004) (Pubitemid 38140063)
36. M. Okai, M. Nieda, A. Tazbirkova, D. Horley, A. Kikuchi, S. Durrant, T. Takahashi, A. Boyd, R. Abraham, H. Yagita, T. Juji and A. Nicol: Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alphagalactosylceramide-pulsed dendritic cells. Vox Sang 83, 250-3 (2002) (Pubitemid 36807274)
37. D. H. Chang, K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, J. Shay, K. Kirchhoff, N. Nishi, Y. Ando, K. Hayashi, H. Hassoun, R. M. Steinman and M. V. Dhodapkar: Sustained expansion of NKT cells and antigen-specific T cells after injection of alphagalactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201, 1503-17 (2005) (Pubitemid 40664093)
38. T. Uchida, S. Horiguchi, Y. Tanaka, H. Yamamoto, N. Kunii, S. Motohashi, M. Taniguchi, T. Nakayama and Y. Okamoto: Phase I study of alphagalactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57, 337-45 (2007) (Pubitemid 350295376)
39. S. Horiguchi, T. Matsuoka, Y. Okamoto, D. Sakurai, K. Kobayashi, H. Chazono, T. Hanazawa and Y. Tanaka: Migration of Tumor Antigen-Pulsed Dendritic Cells After Mucosal Administration in the Human Upper Respiratory Tract. J Clin Immunol 27, 598-604 (2007)
40. P. T. Lee, K. Benlagha, L. Teyton and A. Bendelac: Distinct functional lineages of human Valpha24 natural killer T cells. J Exp Med 195, 637-41 (2002) (Pubitemid 34461508)
41. N. Y. Crowe, J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey and M. J. Smyth: Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202, 1279-88 (2005) (Pubitemid 41586958)